.css-1xsl8rf{width:100%;display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;position:relative;overflow:hidden;background:var(--alert-bg);-webkit-padding-start:var(--chakra-space-4);padding-inline-start:var(--chakra-space-4);-webkit-padding-end:var(--chakra-space-4);padding-inline-end:var(--chakra-space-4);padding-top:var(--chakra-space-1);padding-bottom:var(--chakra-space-1);--alert-fg:var(--chakra-colors-orange-600);--alert-bg:var(--chakra-colors-orange-100);font-weight:var(--chakra-fontWeights-semibold);padding-left:var(--chakra-space-4);}.chakra-ui-dark .css-1xsl8rf:not([data-theme]),[data-theme=dark] .css-1xsl8rf:not([data-theme]),.css-1xsl8rf[data-theme=dark]{--alert-fg:var(--chakra-colors-orange-200);--alert-bg:rgba(251, 211, 141, 0.16);}@media screen and (min-width: 48em){.css-1xsl8rf{padding-left:var(--chakra-space-8);}}Bitte aktivieren Sie Javascript um alle Funktionen nutzen zu können und ihre Nutzererfahrung zu verbessern.

Prof. Dr. Dr. Jan Rybniker

Cologne / DE

University Hospital of Cologne

Vorsitz

13.02.2025
15:15 – 16:45
Scientific symposium
Immune Prevention and Therapy
Lecture hall

Weitere Beteiligungen

13.02.2025
Poster
P-1-132
Intracellular signaling cascades and cell death mechanisms of dendritic cells induced by Mycobacterium tuberculosis infection
Current and Future Challenges in Infectious Diseases
13.02.2025
Poster
P-1-89
Preclinical development of patient-derived anti-PcrV monoclonal antibodies targeting Pseudomonas aeruginosa
Immune Prevention and Therapy
13.02.2025
Poster
P-1-43
Prospective cohort-study for the investigation of the vaccine-induced immune response after vaccination against RESPiratory viruses in patients with hematological and ONcological diseaSEs (RESPONSE)
Immune Prevention and Therapy
13.02.2025
Poster
P-1-65
Deciphering the human B cell response to exotoxin A of Pseudomonas aeruginosa
Immune Prevention and Therapy
13.02.2025
Poster
P-1-62
Targeting Enterococcus faecalis adhesin Ace with patient-derived monoclonal antibodies
Immune Prevention and Therapy
13.02.2025
Poster
P-1-59
Training versus tolerance – Previous adjuvant exposure impairs SARS-CoV-2 spike protein directed immune responses in vitro and in vivo
Immune Prevention and Therapy
13.02.2025
Poster
P-1-57
NLRP3 inflammasomes as dual-hit host-directed targets in Tuberculosis – potent abrogation of necrosis and granuloma formation in vitro and in vivo
Immune Prevention and Therapy
13.02.2025
Poster
P-1-56
Patient-derived monoclonal antibodies to treat Candida infections
Immune Prevention and Therapy
13.02.2025
18:05 – 18:15 8 Min. 2 Min.
Short Talk
S-3-3
Chronic infection induces a broadly neutralizing B cell response to Elastase B of Pseudomonas aeruginosa
Chronic Infections
13.02.2025
18:25 – 18:35 8 Min. 2 Min.
Short Talk
S-3-5
Dysregulated soluble immune checkpoints in plasma of Post-Covid syndrome patients correlate with altered immune phenotypes
Chronic Infections
14.02.2025
Poster
P-2-121
Therapeutic drug monitoring-guided treatment of XDR tuberculosis with an RpoB I491F mutation in a ukrainian patient in Germany, 2023
Antimicrobial Resistance
14.02.2025
Poster
P-2-86
Multi-omics techniques deliver highly accurate diagnostic gene expression signatures for precision medicine in extrapulmonary tuberculosis
Antimicrobial Resistance
14.02.2025
Poster
P-2-87
A highly selective inhibitor of the 1-deoxy-D-xylulose 5-phosphate synthase with good oral bioavailability and activity against MDR tuberculosis
Antimicrobial Resistance
14.02.2025
Poster
P-2-103
Targeting the replication of mycobacterial DNA: corramycin as an antituberculous agent
Antimicrobial Resistance
14.02.2025
Poster
P-2-94
DZIF EX-TB study: Challenges during treatment of extrapulmonary tuberculosis and treatment response assessment
Antimicrobial Resistance